Paid Clinical Trials Arkansas
Discover 627 paid clinical trials in Arkansas. Search by city or condition to find a research study near you that matches your needs across various therapeutic areas.
Lomustine with Temozolomide & RadiationTesting the Addition of the Chemotherapy Drug Lomustine (Gleostine) to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Methylated Glioblastoma
Sponsor:
NRG Oncology
Location:
Code:
NCT05095376
Conditions
Glioblastoma
Gliosarcoma
Eligibility Criteria
Sex: All
Age: 18 - 70
Healthy Volunteers: Not accepted
Interventions
Lomustine
Magnetic Resonance Imaging
Photon Beam Radiation Therapy
Questionnaire Administration
Temozolomide
AtogepantA Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
Sponsor:
AbbVie
Location:
Code:
NCT05711394
Conditions
Episodic Migraine
Eligibility Criteria
Sex: All
Age: 6 - 17
Healthy Volunteers: Not accepted
Interventions
Atogepant
Placebo-Matching Atogepant
Optimizing TreatmentOptimizing Pharmacologic Treatment for Neonatal Opioid Withdrawal Syndrome (OPTimize NOW): A Symptom-Based Dosing Approach
Sponsor:
HELP for NOWS Consortium
Location:
Code:
NCT05980260
Conditions
Neonatal Opiate Withdrawal Syndrome
Eligibility Criteria
Sex: All
Age: 1 - 48
Healthy Volunteers: Not accepted
Interventions
Symptom-based Dosing Approach
Scheduled Opioid Taper Approach
Observational StudyNational Collaborative to Improve Care of Children With Complex Congenital Heart Disease
Sponsor:
Children's Hospital Medical Center, Cincinnati
Location:
Code:
NCT02852031
Conditions
Hypoplastic Left Heart Syndrome (HLHS)
Eligibility Criteria
Sex: All
Age: 0 - 15
Healthy Volunteers: Not accepted
Interventions
Collaborative Learning Network
UpadacitinibA Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
Sponsor:
AbbVie
Location:
Code:
NCT05889182
Conditions
Hidradenitis Suppurativa
Eligibility Criteria
Sex: All
Age: 12+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Placebo
SEVENFACT®SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors
Sponsor:
American Thrombosis and Hemostasis Network
Location:
Code:
NCT04647227
Conditions
Hemophilia A With Inhibitor
Hemophilia B With Inhibitor
Eligibility Criteria
Sex: All
Age: 12 - 70+
Healthy Volunteers: Not accepted
Interventions
coagulation factor VIIa [recombinant]-jncw
Solifenacin vs. ClonidineSolifenacin Compared to Clonidine for Reducing Hot Flashes Among Breast Cancer Patients
Sponsor:
University of Arkansas
Location:
Code:
NCT01530373
Conditions
Hot Flashes
Breast Cancer
Eligibility Criteria
Sex: Female
Age: 18+
Healthy Volunteers: Not accepted
Interventions
solifenacin
Clonidine
ParicalcitolA Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)
Sponsor:
AbbVie
Location:
Code:
NCT04064827
Conditions
Chronic Kidney Disease (CKD)
Secondary Hyperparathyroidism (SHPT)
Eligibility Criteria
Sex: All
Age: 0 - 9
Healthy Volunteers: Not accepted
Interventions
Paricalcitol
TezepelumabEfficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis
Sponsor:
AstraZeneca
Location:
Code:
NCT05583227
Conditions
Eosinophilic Esophagitis
Eligibility Criteria
Sex: All
Age: 12 - 70+
Healthy Volunteers: Not accepted
Interventions
Tezepelumab
Placebo
Upadacitinib vs. AdalimumabStudy to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis
Sponsor:
AbbVie
Location:
Code:
NCT05814627
Conditions
Rheumatoid Arthritis
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Upadacitinib
Adalimumab
Upadacitinib Matching Placebo
Adalimumab Matching Placebo